B2M and diffuse large B-cell lymphoma: However, ongoing studies should reveal the efficacy of ICI- nivolumab (NCT03704714, NCT03749018), pembrolizumab (NCT03990961, NCT03401853), and durvalumab (NCT03003520)- in several combination therapies for R/R DLBCL, and establish the predictive value of B2M mutations in these patients.